The design of novel 17β-hydroxysteroid dehydrogenase type 3 inhibitors

Molecular and Cellular Endocrinology

Volumn 301, Issue 1-2, 2009, Pages 259-265

  Vicker, Nigel ^a   Sharland, Christopher M ^a   Heaton, Wesley B ^a   Gonzalez, Ana M Ramos ^a   Bailey, Helen V ^a   Smith, Andrew ^a   Springall, Jeremy S ^a   Day, Joanna M ^b   Tutill, Helena J ^b   Reed, Michael J ^b   Purohit, Atul ^b   Potter, Barry V L ^a  

^a University of Bath   (United Kingdom)

^b Sterix Ltd   (United Kingdom)

Author keywords

17 HSD3; Cancer; Hydroxysteroid dehydrogenase; Prostate

Indexed keywords

1 [4 [2 (2,4 CHLOROPHENOXY)PHENYLAMINO]PIPERIDIN 1 YL]ETHANONE; 1 [4 [2 (4 CHLOROPHENOXY)PHENYLAMINO]AZEPAN 1 YL]ETHANONE; 1 [4 [2 (4 CHLOROPHENOXY)PHENYLAMINO]PIPERIDIN 1 YL]ETHANONE; 1 ACETYL 5 [2 (4 CHLOROPHENOXY)PHENYLAMINO] 2,3,4,5 TETRAHYDROBENZ[B]AZEPINE; ENZYME INHIBITOR; SCH 451659; TESTOSTERONE 17BETA DEHYDROGENASE; UNCLASSIFIED DRUG; 17BETA HYDROXYSTEROID DEHYDROGENASE TYPE 3; 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3; AZEPINE DERIVATIVE; HYDROXYSTEROID DEHYDROGENASE; PIPERIDINE; PIPERIDINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME INHIBITION; IC 50; MOLECULAR DOCKING; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; CLASSIFICATION; DRUG ANTAGONISM; HUMAN; HYDROPHOBICITY; STRUCTURAL HOMOLOGY; SYNTHESIS;

17-HYDROXYSTEROID DEHYDROGENASES; AZEPINES; CATALYTIC DOMAIN; CELL LINE; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; HYDROPHOBICITY; MODELS, MOLECULAR; PIPERIDINES; STRUCTURAL HOMOLOGY, PROTEIN;

EID: 60249101058     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2008.08.005     Document Type: Article

References (25)

1. Altschul S.F., Madden T.L., Schäffer A.A., Zhang J., Zhang Z., Miller W., and Lipman D.J. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25 (1997) 3389-3402
2. Bailey H.V., Heaton W., Vicker N., and Potter B.V.L. Rapid microwave-assisted reductive amination of ketones with anilines. Synlett. (2006) 2444-2448
3. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., and Bourne P.E. The protein data bank. Nucleic Acids Res. 28 (2000) 235-242
4. Breitling R., Laubner D., and Adamski J. Structure-based phylogenetic analysis of short-chain alcohol dehydrogenases and reclassification of the 17beta-hydroxysteroid dehydrogenase family. Mol. Biol. Evol. 18 (2001) 2154-2161
5. Day J.M., Tutill H.J., Newman S.P., Purohit A., Lawrence H.R., Vicker N., Potter B.V.L., and Reed M.J. 17β-Hydroxysteroid dehydrogenase type 1 and type 2: association between mRNA expression and activity in cell lines. Mol. Cell. Endocrinol. 248 (2006) 246-249
6. Day, J.M., Tutill, H.J., Foster, P.A., Bailey, H.V., Heaton, W.B., Sharland, C.M., Vicker, N., Potter, B.V.L., Purohit, A., Reed, M.J., this issue. Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17β-hydroxysteroid dehydrogenase type 3.
7. Fink B.E., Gavai A.V., Tokarski J.S., Goyal B., Misra R., Xiao H.Y., Kimball S.D., Han W.C., Norris D., Spires T.E., You D., Gottardis M.M., Lorenzi M.V., and Vite G.D. Identification of a novel series of tetrahydrodibenzazocines as inhibitors of 17β-hydroxysteroid dehydrogenase type 3. Bioorg. Med. Chem. Lett. 16 (2006) 1532-1536
8. Guzi T.J., Liu Y., Doll R.J., Saksena A., Girijavallabhan V.M., and Pachter J.A. 17β-Hydroxysteroid dehydrogenase type 3; Inhibitors for the treatment of androgen dependent diseases. WO 046111 A1 (2004)
9. Jones G., Willett P., Glen R.C., Leach A.R., and Taylor R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 267 (1997) 727-748
10. Koh E., Noda T., Kanaya J., and Namiki M. Differential expression of 17β-hydroxysteroid dehydrogenase isozyme genes in prostate cancer and noncancer tissues. Prostate 53 (2002) 154-159
11. Krieger E., Koraimann G., and Vriend G. Increasing the precision of comparative models with YASARA NOVA-a self-parameterizing force field. Proteins: Struct. Funct. Genet. 47 (2002) 393-402
12. Laplante Y., and Poirier D. Proliferative effect of androst-4-ene-3,17-dione and its metabolites in the androgen-sensitive LNCaP cell line. Steroids 73 (2008) 266-271
13. Laskowski R.A., MacArthur M.W., Moss D.S., and Thornton J.M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Cryst. 26 (1993) 283-291
14. Lukacik P., Kavanagh K.L., and Oppermann U. Structure and function of human 17β-hydroxysteroid dehydrogenases. Mol. Cell. Endocrinol. 248 (2006) 61-71
15. Luu-The V., Belanger A., and Labrie F. Androgen biosynthetic pathways in the human prostate. Best Prac. Res. Clin. Endocrinol. Metab. 22 (2008) 207-221
16. Moeller G., and Adamski J. Multifunctionality of human 17β-hydroxysteroid dehydrogenases. Mol. Cell. Endocrinol. 248 (2006) 47-55
17. Moghrabi N., and Andersson S. 17beta-hydroxysteroid dehydrogenases: physiological roles in health and disease. Trends Endocrinol. Metab. 9 (1998) 265-270
18. Pachter J., Huryk R., Ramos R., Meredith J., Weinbauer G., and Guzi T. Inhibition of 17β-HSD as a novel approach to treat androgen dependent prostate cancer: efficacy in cynomolgus monkeys. 96th Annual Meeting of the American Association for Cancer Research. Anaheim, California (2005)
19. Penning T.M., Burczynski M.E., Jez J.M., Hung C.F., Lin H.K., Ma H., Moore M., Palackal N., and Ratnam K. Human 3α-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem. J. 351 (2000) 67-77
20. Poirier D. Inhibitors of 17β-hydroxysteroid dehydrogenases. Curr. Med. Chem. 10 (2003) 453-477
21. Tanaka N., Nonaka T., Tanabe T., Yoshimoto T., Tsuru D., and Mitsui Y. Crystal structures of the binary and ternary complexes of 7 alpha-hydroxysteroid dehydrogenase from Escherichia coli. Biochemistry 35 (1996) 7715-7730
22. Thompson J.D., Gibson T.J., Plewniak F., Jeanmougin F., and Higgins D.G. The ClustalX windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res. 24 (1997) 4876-4882
23. van Bokhoven A., Varella-Garcia M., Korch C., Johannes W.U., Smith E.E., Miller H.L., Nordeen S.K., Miller G.J., and Lucia M.S. Molecular characterization of human prostate carcinoma cell lines. Prostate 57 (2003) 205-225
24. Vicker N., Day J.M., Bailey H.V., Heaton W.B., Gonzalez A.M.R., Sharland C.M., Reed M.J., Purohit A., and Potter B.V.L. Preparation of substituted aliphatic amines for use as anticancer or therapeutic agents inhibiting 17β-hydroxysteroid dehydrogenase. WO 2007003934 A2 (2007)
25. Vriend G. WHAT IF: a molecular modeling and drug design program. J. Mol. Graph. 8 (1990) 52-56